Search Results - "Abramov, M E"

Refine Results
  1. 1

    Treatment tactics of non-small-cell lung cancer with erlotinib: literature review and description of a clinical case by Borisova, E. I., Gutorov, S. L., Abramov, M. E.

    Published in Medicinskij sovet (09-12-2019)
    “…Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase domain, which has shown effectiveness in the treatment of non-small cell lung cancer with…”
    Get full text
    Journal Article
  2. 2

    Ixabepilone: new perspectives for its use in breast cancer by A. A. Mescheryakov, E. V. Lubennikova, M. E. Abramov

    Published in Medicinskij sovet (11-11-2018)
    “…Despite significant advances in recent years, the drug therapy for breast cancer (BC) is still based on chemotherapy. The introduction of new effective…”
    Get full text
    Journal Article
  3. 3

    TEYSUNO: FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH DISSEMINATED GASTRIC CANCER by O. O. GORDEEVA, M. E. ABRAMOV, A. N. LUD

    Published in Medicinskij sovet (01-06-2017)
    “…Gastric cancer is one of the leading causes of death among all cancers in Russia. Progression-free and overall survival cannot be drastically changed by…”
    Get full text
    Journal Article
  4. 4

    Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience by E. I. Borisova, S. P. Gutorov, G. V. Vyshinskaya, N. V. Dobrova, M. E. Abramov

    Published in Medicinskij sovet (11-11-2018)
    “…The article considers the place of nab-paclitaxel in the treatment of metastatic breast cancer. A number of studies have shown high efficacy and acceptable…”
    Get full text
    Journal Article
  5. 5

    The role of erythropoietins in cancer therapy by O. E. Kondratieva, M. E. Abramov, G. V. Vyshinskaya, S. L. Gutorov, E. I. Borisova, E. V. Cherniglazova

    Published in Medicinskij sovet (19-07-2018)
    “…Anemia is a common hematological complication in cancer patients receiving chemotherapy. Reduction of hemoglobin level is accompanied by a significant…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Risk factors of adverse outcome of COVID-19 and experience of Tocilizumab administration in patients on maintenance hemodialysis due to diabetic kidney disease by Zeltyn-Abramov, E. M., Lysenko, M. A., Frolova, N. F., Markova, T. N., Belavina, N. I., Klochkova, N. N., Kondrashkina, S. V., Iskhakov, R. T., Ushakova, A. I.

    Published in Sakharnyĭ diabet (14-02-2021)
    “…BACKGROUND : Patients with Type 2 Diabetes (T2DM) and patients on maintenance hemodialysis (MHD) are at a high risk of adverse clinical course of COVID-19. To…”
    Get full text
    Journal Article
  8. 8

    INFLUENCE OF THE RECOMBINANT TUMOR NECROSIS FACTOR THYMOSIN-α1 ON ANGIOGENESIS IN DISSEMINATED SKIN MELANOMA PATIENTS by I. A. KOROLEVA, E. G. SLAVINA, A. I. CHERTKOVA, V. A. NURTDINOVA, E. K. SHOUA, M. E. ABRAMOV, Z. G. KADAGIDZE

    Published in Medicinskij sovet (01-06-2017)
    “…The article covers the results of clinical application of a domestic drug based on recombinant tumor necrosis factor-alphathymosin-alpha1 (Refnot) in 20…”
    Get full text
    Journal Article
  9. 9

    Reversible pulmonary hypertension in post -renaltransp lantation patient with longst anding arteriovenous fistula by E. M. Zeltyn-Abramov, R. T. Iskhakov, L. Yu. Artyukhina, E. S. Ivanova, O. V. Manchenko, N. I. Belavina, N. A. Tomilina

    “…Case report of reversible high pulmonary hypertension (PH) in patient with successful kidney transplantation (KT) is presented. The distinction of the case was…”
    Get full text
    Journal Article
  10. 10

    EXTERNAL MYOCARDIAL RUPTURE IN ACUTE PHASE OF MYOCARDIAL INFARCTION: CLINICAL AND INSTRUMENTAL PREDICTORS by E. M. Zeltyn’-Abramov, A. E. Radzevich

    Published in Rossiĭskiĭ kardiologicheskiĭ zhurnal (01-04-2010)
    “…The retrospective univariable and multivariable analyses of 263 medical histories of patients with acute myocardial infarction, AMI (61 cases of external…”
    Get full text
    Journal Article
  11. 11

    Determination of variations of the primary structure of the UGT1A1, DPYD, GSTP1, and ABCB1 genes involved in the metabolism of antitumor agents by Titov, S. V., Heydarov, R. N., Abramov, M. E., Timofeev, E. N., Mikhailovich, V. M.

    Published in Biophysics (Oxford) (01-03-2017)
    “…A individual approach to the treatment of cancer patients, which takes the genetic features of the patient’s metabolism into account, allows one to choose an…”
    Get full text
    Journal Article
  12. 12

    BRCA-associated ovarian cancer: a review of the current literature by Tikhomirova, T. E., Tyulyandina, A. S., Rumyantsev, A. A., Abramov, M. E., Anokhin, A. Yu, Lud, A. N., Tjulandin, S. A.

    Published in Tazovaâ hirurgiâ i onkologiâ (Online) (07-09-2022)
    “…Ovarian cancer is a heterogeneous disease and is the leading cause of mortality among all gynecological malignancies. The disease is characterized by a high…”
    Get full text
    Journal Article
  13. 13

    Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma by Tronov, V A, Artamonov, D N, Abramov, M E, Gorbacheva, L B

    Published in T͡S︡itologii͡a (2011)
    “…Melanoma is a highly aggressive neoplastic disease attributed to transformed melanocytes. The efficacy of regimens of cytotoxic chemotherapy for advanced stage…”
    Get more information
    Journal Article
  14. 14

    Cellular markers based on DNA repair (BER, MMR) expression of MLH1, MSH2, FasR and death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma patients by Tronov, V. A., Artamonov, D. N., Abramov, M. E., Gorbacheva, L. B.

    Published in Cell and tissue biology (01-02-2011)
    “…Melanoma is a highly aggressive tumor of melanocytes. The efficacy of different cytotoxic chemotherapy regimens does not exceed 20%. The search for markers for…”
    Get full text
    Journal Article
  15. 15

    Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma by Tronov, V A, Artamonov, D N, Abramov, M E, Gorbacheva, L B, Lichinitser, M R

    Published in Voprosy onkologij (2011)
    “…Patients with advanced malignant melanoma have poor prognosis as conventional chemotherapy induces complete response in a very small fraction (not more than…”
    Get more information
    Journal Article
  16. 16
  17. 17

    Thrombolytic therapy and cardiac free wall rupture in patients with acute myocardial infarction by E M Zeltyn-Abramov, A E Radzevitch

    “…The possible connection between thrombolytic therapy (TT) and the risk of left ventricle free wall rupture (LVFWR) in patients with acute myocardial infarction…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom by L G Zhukova, M E Abramov, Yu V Vakhabova, A N Lud, A A Obukhov, M R Lichinitser

    “…Внедрение в клиническую практику большого количества эффективных схем цитостатической терапии позволило, с одной стороны, сделать излечимыми ряд…”
    Get full text
    Journal Article
  20. 20

    Clinical and instrumental predictors of upcoming cardiac free wall rupture due to acute miocardial infarction by E M Zeltyn-Abramov, A E Radzevitch, N I Belavina, V N Nesvetov, N N Klochcova

    “…Medical records and autopsy reports of 839 patients admitted to City Hospital N52 were reviewed. 42 patients died from cardiac free wall rupture…”
    Get full text
    Journal Article